RecruitingNCT05577247

Belief Updating in Treatment Resistant Depression

How the Brain Encodes Beliefs: A Functional Magnetic Resonance Imaging Study of the Belief Updating in Treatment Resistant Depression.


Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

60 participants

Start Date

May 13, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Major depressive disorder (MDD) is characterized by a cognitive triad of negative beliefs about oneself, the future and the world. For example, depressed patients hold persistently negative expectations about the future, despite contradictory evidence, and these strong negative beliefs are thought to play an important role in the maintenance of depressive symptoms and potentially in treatment resistance. Indeed, one out of three patients with major depressive disorder does not respond to conventional, monoaminergic treatments, which has led to the concept of treatment resistant depression (TRD). It is unknown how the brain encodes the strong negative beliefs that are insensitive to positive disconfirming information in TRD patients, and how these neural underpinnings of maladaptive belief updating are altered by antidepressant treatment. The principal objective of this study is to gain insight into the brain mechanisms of belief updating about the future in TRD patients before and after starting ketamine treatment. The results of this study are expected to provide a better understanding of the neurocognitive mechanisms of belief-updating in depressed patients, and how these mechanisms contribute to clinical improvement following ketamine antidepressant treatment.


Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how people with treatment-resistant depression update their beliefs in response to new information. Participants will complete thinking tasks while starting a new type of antidepressant medication that targets glutamate receptors (a different brain pathway than most antidepressants). The goal is to understand how this treatment changes thought patterns. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with major depressive disorder (MDD) - Your score on a standard depression scale (MADRS) is 20 or higher - You have not responded to at least 2 different antidepressant treatments - You are starting a new treatment involving glutamate-targeting medications **You may NOT be eligible if...** - You have another mental health diagnosis such as bipolar disorder, schizophrenia, PTSD, OCD, or substance use disorder - You have difficulty understanding French (study is conducted in French) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERfunctional magnetic resonance imaging

Patients treated with ketamine antidepressants will be tested with fMRI before or 24h after a single ketamine infusion administered in the clinical setting.


Locations(1)

GH Pitié Salpêtrière

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05577247


Related Trials